EPPIC-Net: Novaremed Painful Diabetic Peripheral Neuropathy ISA
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety and efficacy of the current hard
gelatin capsule formulation of NRD135S.E1 80 mg once daily in the treatment of PDPN when
administered for 12 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
James P. Rathmell, MD
Collaborators:
Icahn School of Medicine at Mount Sinai National Institute of Neurological Disorders and Stroke (NINDS) New York University